Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease

LCD Information Document Information Source LCD ID N/A LCD ID L38278 Original ICD-9 LCD ID Not Applicable LCD Title Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease Proposed LCD in Comment Period N/A Source Proposed LCD DL38278 Opens in a new window Original Effective Date For services performed on or after 11/22/2020 Revision Effective Date For services performed on or after 08/03/2025 Revision Ending Date N/A Retirement Date N/A Notice Period Start Date 06/19/2025 Notice Period End Date 08/02/2025 CPT codes, descriptions, and other data only are copyright 2025 American Medical Association. All Rights Reserved. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. CPT is a registered trademark of the American Medical Association. Current Dental Terminology © 2025 American Dental Association. All rights reserved. Copyright © 2026, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution, or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at ub04@aha.org or 312‐422‐3366. Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates. Issue Issue Description 1. Expands stenosis range to 40-90% and alters vessel specific limitations to align with guidelines 2. Removes the limitation on BMI, and aortic stenosis based on new data 3. Defines intermediate and high risk by 2021 Guidelines 4. Allows FFRct as an alternative, but not in conjunction, to stress test Issue - Explanation of Change Between Proposed LCD and Final LCD 1. CMS National Coverage Policy regulations were updated. 2. Editorial and typographical corrections were made. CMS National Coverage Policy Title XVIII of the Social Security Act, §1862 (a)(1)(A) allows coverage and payment for only those services that are considered to be reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member Title XVIII of the Social Security Act, §1862 (a)(1)(D) items and services related to research and experimentation Title XVIII of the Social Security Act, §1862 (a)(7) states Medicare will not cover any services or procedures associated with routine physical checkups 42 CFR §410.32 indicates that diagnostic tests may only be ordered by the treating physician (or other treating practitioner acting within the scope of his or her license and Medicare requirements) The Protecting Access to Medicare Act (PAMA) of 2014, Section 218(b), established a new program to increase the rate of appropriate advanced diagnostic imaging services provided to Medicare beneficiaries CMS Internet-Only Manual, Pub 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 4, §220.1 Computed Tomography (CT) Coverage Indications, Limitations, and/or Medical Necessity United States (U.S.) Food and Drug Administration (FDA) - approved FFRct technology may be considered reasonable and necessary in the management of patients with: a. Intermediate risk* patients with acute or stable chest pain and with no known history coronary artery stenosis with finding of 40-90% in proximal or middle coronary artery on coronary computed tomography angiography (CCTA)1 OR b. Intermediate risk* patients with acute chest pain and known non-obstructive (<50%) coronary artery disease (CAD) coronary artery stenosis with finding of 40-90% stenosis on CCTA1 OR c. Stable nonobstructive CAD (<50% stenosis) with persistent** symptoms requiring further test, and finding of 40-90% stenosis on CCTA1 AND Not in conjunction with stress testing* (unless CCTA was not sufficient quality for FFRct, and an alternative study is needed) *Intermediate and high-risk and stress test as defined in the 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain1 **Persistent symptoms are unacceptable ischemia-related symptoms despite maximally tolerated medical therapy. FFRct is not considered reasonable in the following clinical circumstances: Prior placement of prosthetic valves Prior placement of grafts in coronary bypass surgery Suspicion of acute coronary syndrome (where myocardial infarction (MI) or unstable angina have not been ruled out) Intracoronary metallic stent Status post-heart transplantation Recent MI (30 days or less) Prior pacemaker or defibrillator lead placement Newly diagnosed systolic heart failure, with no prior left heart catheterization Left main CAD with Intermediated Coronary Stenosis (lumen reduction less than or equal to 40%) Non-obstructing stenosis (<50% of all major epicardial vessels) on computed tomography angiography (CTA) or catheterization in the past 12 months, in the absence of a new symptom complex If turnaround times may impact prompt clinical care decisions This service should be performed in a patient with stable coronary symptoms. It should not be performed until after the base study (CCTA) has been completed and interpreted. If higher grade stenoses (i.e., greater than 90%) are present, this study is not medically necessary, as the patient should proceed to catheterization. Similarly, low-grade stenoses (less than 40%) do not require additional confirmatory data. This should be performed as an alternative to stress testing. Background The concept of invasive FFR as a diagnostic tool was introduced in the early 1990s. The FAME and FAME-II trials supported an FFR-wire guided revascularization strategy as opposed to purely angiographically guided revascularization.2 The National Cardiovascular Data Registry demonstrated a low diagnostic yield from traditional exercise stress testing when the patient progressed to invasive coronary angiography (ICA). FFR is considered the gold standard for assessing the hemodynamic significance of intermediate coronary stenosis by measuring the pressure difference across a coronary artery stenosis.3 Intracoronary catheter pressure measurement before and after the stenosis are compared, and FFR of 0.80 correlates with a 20% pressure drop after the stenosis. This measurement can help determine if the vessel narrowing is limiting blood flow and assess the need for revascularization or stenting. Clinical studies have demonstrated that invasive FFR reduces unnecessary stenting procedures and associated risk.2,4 The use of invasive FFR is supported by the Society of Cardiac Angiography and Interventions (SCAI) and American College of Cardiology (ACC).4,5 Noninvasive FFR is an alternative modality to gain this information without the need for invasive intracoronary instrumentation in patients with known or suspected CAD. FFRct is a FFR derived from computed tomography that relies on computer-assisted processing of CCTA images to estimate coronary blood flow changes related to coronary artery stenoses. Based on physical theories of fluid dynamic modeling, FFRct is a post-processing software for analyzing previously acquired digital imaging from CCTA. Limitations include that the technology is dependent on the image quality of the CCTA, the images must be sent out for post-processing; therefore, real time results are not feasible, and how to apply FFRct results to clinical practice is still in development. Emerging technologies include virtual FFR (vFFR), where the measurements are based on a 3-D image of coronary vessels created by the software using x-ray angiographic imaging. Angio-derived FFR is calculated at the time of coronary angiogram. Persistent CAD symptoms are unacceptable ischemia-related symptoms that persist despite optimal medical therapy. Optimal medical therapy is defined by the ISCHEMIA trial protocol6 as unacceptable ischemia-related symptoms despite maximally tolerated medical therapy. This includes at least 2 anti-anginal drugs from different drug classes added to beta-blocker therapy and titrated to maximally tolerated doses before medical therapy is considered to have failed.6 Summary of Evidence The analysis of CAD by non-invasive coronary computed tomographic analysis has been limited by low specificity. The addition of computer derived flow analysis of the CTA data has added the potential for a non-invasive test that yields both anatomic and functional data. This emerging technology aims to reduce the need for invasive cardiac procedures and associated risks. The Determination of Fractional Flow Reserve by Anatomic Computed Tomographic Angiography (DeFACTO) study compared the first iteration of FFRct technology against invasive angiography and FFR in patients with suspected or known CAD, but did not achieve the pre-specified target accuracy.3 Another study, DISCOVER-FLOW, demonstrated an accuracy of 84.6%.7 A second iteration of the FFRct algorithm was tested against invasive angiography with FFR in 254 patients with suspected CAD in the NXT (Analysis of Coronary Blood Flow Using CT Angiography-Next Steps) trial. This study reported a diagnostic accuracy, sensitivity, specificity, positive predictive value (PPV) and negative predictive value of 81%, 86%, 79%, 65% and 83% respectively.8 In this trial, 484 vessels in 254 patients and found that FFRct significantly improved the per patient specificity and PPV (32% to 84% and 40% to 65%, respectively) and the per vessel specificity and PPV (60% to 86% and 33% to 67%, respectively) compared with CTA. However, this does not translate into benefit compared to CTA alone for identifying patients whose invasive FFR will warrant intervention, and 35% of the abnormal results were false positives.9 A sub analysis of the NXT study evaluated 206 participants and reported no cardiac death or MIs in participants with normal FFRct at a median follow-up of 4.7 years. The authors concluded that an FFRct value of 0.8 or less is a predictor of long-term outcomes driven by planned and unplanned revascularization and is superior to clinically significant stenosis on coronary CCTA.10 The PROMISE study demonstrated that patients with an FFRct less than or equal to 0.80 were significantly more likely to have coronary revascularization and to meet the composite endpoint of major adverse cardiac events or revascularization than those with FFRct greater than 0.80.9 The study also showed that reserving ICA for patients with FFRct less than or equal to 0.80 could reduce the rate of performing ICA by 28%. The initial trial did include a CCTA strategy, which did not improve outcomes after 2 years of follow-up. The study, a retrospective, observational, cohort study, also highlighted the dependence of FFRct on the quality of the CCTA images being post-processed, with one-third of the images submitted for review of insufficient quality.11 The FFRct RIPCORD study involved 200 patients and compared the management of patients by cardiologists with and without the addition of FFRct data to the baseline CTA data. The additional FFRct data changed the management plan for 72 patients (36%) based on lesion severity assessment. With inclusion of changes in the percutaneous coronary intervention (PCI) target vessel, patient management was altered in 44% of patients.12 In the PLATFORM study, 584 patients were allocated to noninvasive or ICA cohorts. Each cohort was divided into standard of care and FFRct guided care groups. The 90-day primary end point of invasive catheterization without obstructive CAD occurred in significantly fewer patients with FFRct guided care than usual care in both cohorts. This prospective, longitudinal comparative effectiveness study demonstrated that in an appropriately selected population for CCTA, 88% of the studies were of sufficient quality to perform FFRct on the derived images.13-15 From the initial group of patients, 116 were identified to undergo ICA. Fifty-two underwent CTA/FFRct resulting in the cancellation of the ICA in 40 (77%). At 1 year, they reported no major cardiovascular events in this group.16 While this is promising, there are significant limitations. The group was not allocated randomly, and patients in the FFRct arm were younger, had a lower incidence of diabetes, and lower pretest probability of obstructive CAD. The small sample size was not powered to show a difference in clinical events and major cardiac events; therefore, this data cannot be extrapolated to a larger, more diverse population. The Assessing Diagnostic Value of non-invasive FFRct in Coronary Care (ADVANCE) registry is a large prospective registry that included 5,083 patients with symptoms suggestive of angina from 38 centers in Europe, North America and Japan. There was a change in management pathway in 66% of patients, after FFRct data were available compared with CCTA alone.17 At 1 year, the authors report that patients with FFRct ≤0.80 were less frequently referred for ICA (from 62.9% to 252.9%, P < 0.001) and reported the prevalence of major events was low and similar between the cohorts.18,19 This data is limited by the observational nature of the study with the inability to adjust for confounding factors such as additional studies being used to make the ultimate decision of whether or not to proceed with ICA, the risk from multiple biases including referral bias, attrition bias, and other bias, and variable experience with FFRct among the study sites. A recent Danish observational study that included 3,674 patients with suspected CAD who underwent CCTA with FFRct for stenosis between 30% and 90% had supportive findings for using this technology in care management. Patients with FFRct greater than 0.8 had similar outcomes to patients without obstructive disease on CCTA (i.e., less than 30%). By contrast, patients with FFRct ≤0.8 had significantly more major adverse coronary events (9.6% vs. 1.4%).20 A 2017 systematic review by Cook, et al. evaluated 908 vessels from 536 patients in 5 studies. They reported that the per-vessel diagnostic accuracy of FFRct was 81.9% (95% CI: 79.4-84.4%). They further broke down the diagnostic accuracy of FFRct by the FFRct values and reported values below 0.06, 0.06-0.07, 0.70-0.80, 0.80-0.90, and above 0.9 was 86.4%, 74.7%, 46.1%, 87.3% and 97.9%, respectively. This data showed clustering of large numbers of FFRct values in the >0.9 range, where the correlation between FFRct and FFR was very high. However, when approaching the 0.8 level, the correlation becomes less robust. Of significance, the FFRct correlation showed 82% overall diagnostic accuracy through threshold was met for FFRct values lower than 0.63 or above 0.83; however, the correlation between the 0.7 to 0.8 group was notably lower at 46.1%. More stringent 95% and 98% diagnostic accuracy thresholds were met for FFRct values lower than 0.53 or above 0.93 and lower than 0.47 or above 0.99, respectively.21 The 2019 PACIFIC trial is a prospective study comparing 208 patients with suspected stable CAD who underwent coronary CTA with FFRct calculations, single-photon emission computed tomography (SPECT), positron emission tomography (PET), and invasive FFR. Eighty-three percent of vessels could be evaluated with FFRct, which demonstrated a diagnostic accuracy, sensitivity, and specificity of 87%, 90%, and 86% on a per-vessel basis and 78%, 96%, and 63% on a per-patient basis, respectively. FFRct outperformed coronary CTA and SPECT, and PET for vessel-specific ischemia, while PET performed better for per-patient and intention-to-diagnosis analysis.22 The 2019 ReASSESS trial is a single centered prospective study where 143 patients scheduled to undergo invasive coronary angiogram with stable angina also underwent FFRct and SPECT. They found FFRct had similar overall diagnostic accuracy, and FFRct had higher diagnostic sensitivity than SPECT (91% (95% CI: 81% to 97%) versus 41% (95% CI: 29% to 55%; p<0.001)). The specificity of FFRct compared to invasive FFR was 55% (86% SPECT) with PPV a 58% and overall accuracy of 70%. In analyzing diagnostic performance for detection of CAD on an intention to treat basis PPV was 47% with accuracy of 63%.23 A 2020 meta-analysis of 77 studies found that FFRct identifies clinically significant stenosis in patients with suspected CAD with a high sensitivity (mean 85%, 95% CI: 81-88%), but low to moderate specificity (mean 69%, 95% CI: 64% to 74%).24 Additional literature recommended by the American College of Cardiology (ACC) provided better insight into current anatomic applications and the accuracy of the determinations. The SYNTAX family of randomized controlled trials demonstrated that PCI or stenting is a viable option in patients with 3-vessel disease and applying this technology to decision-making regarding coronary artery bypass graft (CABG) or PCI. Use of FFRct to determine a functional SYNTAX Score (in the SYNTAX III study) reclassified 30% of patients to a lower score.25-27 ACC also provided additional literature supporting the accuracy of CCTA in obese patients.28,29 Accuracy with FFRct has been validated in several studies compared to invasive FFR to be around 80% in patients with stable CAD. While non-invasive FFRct shows promise as comparable or even superior performance to some existing technologies, such as stress test or SPECT, it falls behind invasive FFR in accuracy and PPV. The PPV ranges from 52-65% among the various studies.8,22,23 There is also a risk of false positive of up to 35%, so confirmation at the time of invasive coronary angiogram confirmation of the lesion is often performed prior to before stent placement.9 Numerous pivotal trials repeatedly exclude patients with body mass index (BMI) >35 in inclusion criteria. The ADVANCE registry indicated that high BMI was not a statistically significant predictor of CCTA quality rejection. Many patients with a BMI >39 were successfully able to receive the FFRct service.30 Additional literature suggests that CCTA provide high diagnostic accuracy in both obese and non-obese population.29 A sub-analysis from the PROMISE trial including 606 patients with BMI ≥40 showed a slightly higher (not statistically significant) yield for positive noninvasive results (13.1% for BMI ≥35 compared to 12.1% with BMI <35). Significantly the ability to conduct and interpret the test was not limited if the scanner could accommodate higher BMIs for the CCTA.31 A 2021 prospective study of 42 patients (68 vessels) with severe aortic stenosis underwent FFR and CTA with 88.2% of vessels having interpretable CTA to allow FFRct analysis. There was a strong positive correlation between FFR and FFRct (p<0.0001). The authors conclude that CTA and FFRct are safe and feasible with diagnostic accuracy in patients with severe aortic stenosis.32 Societal Guidance The use of invasive FFR is endorsed by multiple societies, including the Society of Cardiac Angiography and Interventions (SCAI) and ACC4,33 and European Society of Cardiology.34 The 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: Executive Summary1 added recommendation that FFR can be useful for diagnosis of vessel-specific ischemia and to guide decision-making regarding the use of ICA for 3 categories of patients.1 a. Intermediate-risk and previously unknown coronary stenosis of 40-90% in proximal or middle coronary artery.b. Intermediate-risk with acute chest pain and known coronary stenosis of 40-90% in proximal or middle coronary artery.c. Known nonobstructive coronary with stable chest pain and stenosis from 40-90% on CCTA. The level of evidence was graded B-NR which represents moderate quality evidence from 1 or more well-designed, non-randomized study and/or meta-analysis of such studies, and a Class of Recommendation (COR) 2a which is moderate strength of recommendation which means benefits are felt to outweigh risk. In the clinical pathways they recommend FFRct or stress test. They stated an advantage of FFRct is not needing to order an additional test but should not be ordered in cases where CCTA imaging may be suboptimal or there is extensive plaque present when stress test is preferred. Additionally, FFRct should not be performed when a delay in the results could impact patient care. Analysis of Evidence (Rationale for Determination) These and other studies were discussed by the assembled subject matters experts in a formal CAC discussion convened by Noridian on June 18, 2019. Based on a review of the literature there was a consensus that FFRct is a useful modality in the guidance of and assessment of stable CAD. At the time of the initial policy there was not sufficient evidence to allow for obesity (BMI >39) and evidence supported vessel specific restrictions within stenosis range of 40-70% range. Since this local coverage determination (LCD) became active, the 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: Executive Summary was published with guidelines for use of FFRct with a moderate strength recommendation to expand the role of FFRct in specific clinical settings as an alternative to stress test.1 The LCD has been updated to reflect these guideline changes. The guidelines utilize FFRct as a sequential test. Therefore, the patient must meet the criteria specified within the algorithms to qualify for CCTA. If CCTA is performed and reveals 40-90% stenosis in the proximal or middle coronary artery than FFRct or stress test may be performed. Based on these guidelines the intermediate stenosis range on CCTA has been expanded to 40-90%, vessel specific limits revised, and expansion to stable chest pain has been added to align with the clinical scenarios specified in the guidelines. This does not reverse the previously established position that the technology is not for use in the high-risk patients or when MI has not been excluded. It should not be performed until the base study (CCTA) has been completed and interpreted and should not be relied upon when a delay in the results could impact patient care. The 2021 Guidelines recommendations provide the option of FFRct or stress test in the clinical settings which it has been determined to be an alternative to stress test. Therefore, FFRct should be performed as an alternative to stress testing. Based on this recommendation a new requirement has been added that the FFRct will not be covered in conjunction with stress testing unless CCTA was not sufficiently quality for FFRct, and an alternative study is needed. While the FFRct offers the benefit of another test not needing to be performed at a separate time, clinical judgement will be necessary to limit to clinical circumstances that a high-quality FFRct study will be expected. The severe obesity is removed as a limitation based on publication of new literature to support its use in patients with BMI >39 if the scanner used for CCTA can enable high quality images in setting of severe obesity. The limitation on aortic stenosis was removed based on new literature demonstrating accuracy in this population.

United States (U.S.) Food and Drug Administration (FDA) - approved FFRct technology may be considered reasonable and necessary in the management of patients with: a. Intermediate risk* patients with acute or stable chest pain and with no known history coronary artery stenosis with finding of 40-90% in proximal or middle coronary artery on coronary computed tomography angiography (CCTA) 1 OR b. Intermediate risk* patients with acute chest pain and known non-obstructive ( 1 OR c. Stable nonobstructive CAD ( 1 AND Not in conjunction with stress testing* (unless CCTA was not sufficient quality for FFRct, and an alternative study is needed) *Intermediate and high-risk and stress test as defined in the 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain 1 **Persistent symptoms are unacceptable ischemia-related symptoms despite maximally tolerated medical therapy. FFRct is not considered reasonable in the following clinical circumstances: Prior placement of prosthetic valves Prior placement of grafts in coronary bypass surgery Suspicion of acute coronary syndrome (where myocardial infarction (MI) or unstable angina have not been ruled out) Intracoronary metallic stent Status post-heart transplantation Recent MI (30 days or less) Prior pacemaker or defibrillator lead placement Newly diagnosed systolic heart failure, with no prior left heart catheterization Left main CAD with Intermediated Coronary Stenosis (lumen reduction less than or equal to 40%) Non-obstructing stenosis ( If turnaround times may impact prompt clinical care decisions This service should be performed in a patient with stable coronary symptoms. It should not be performed until after the base study (CCTA) has been completed and interpreted. If higher grade stenoses (i.e., greater than 90%) are present, this study is not medically necessary, as the patient should proceed to catheterization. Similarly, low-grade stenoses (less than 40%) do not require additional confirmatory data. This should be performed as an alternative to stress testing. Background The concept of invasive FFR as a diagnostic tool was introduced in the early 1990s. The FAME and FAME-II trials supported an FFR-wire guided revascularization strategy as opposed to purely angiographically guided revascularization. 2 The National Cardiovascular Data Registry demonstrated a low diagnostic yield from traditional exercise stress testing when the patient progressed to invasive coronary angiography (ICA). FFR is considered the gold standard for assessing the hemodynamic significance of intermediate coronary stenosis by measuring the pressure difference across a coronary artery stenosis. 3 Intracoronary catheter pressure measurement before and after the stenosis are compared, and FFR of 0.80 correlates with a 20% pressure drop after the stenosis. This measurement can help determine if the vessel narrowing is limiting blood flow and assess the need for revascularization or stenting. Clinical studies have demonstrated that invasive FFR reduces unnecessary stenting procedures and associated risk. 2,4 The use of invasive FFR is supported by the Society of Cardiac Angiography and Interventions (SCAI) and American College of Cardiology (ACC). 4,5 Noninvasive FFR is an alternative modality to gain this information without the need for invasive intracoronary instrumentation in patients with known or suspected CAD. FFRct is a FFR derived from computed tomography that relies on computer-assisted processing of CCTA images to estimate coronary blood flow changes related to coronary artery stenoses. Based on physical theories of fluid dynamic modeling, FFRct is a post-processing software for analyzing previously acquired digital imaging from CCTA. Limitations include that the technology is dependent on the image quality of the CCTA, the images must be sent out for post-processing; therefore, real time results are not feasible, and how to apply FFRct results to clinical practice is still in development. Emerging technologies include virtual FFR (vFFR), where the measurements are based on a 3-D image of coronary vessels created by the software using x-ray angiographic imaging. Angio-derived FFR is calculated at the time of coronary angiogram. Persistent CAD symptoms are unacceptable ischemia-related symptoms that persist despite optimal medical therapy. Optimal medical therapy is defined by the ISCHEMIA trial protocol 6 as unacceptable ischemia-related symptoms despite maximally tolerated medical therapy. This includes at least 2 anti-anginal drugs from different drug classes added to beta-blocker therapy and titrated to maximally tolerated doses before medical therapy is considered to have failed. 6